The potential multiple-sclerosis application of Vaccinex Inc.'s preclinical antibody VX15 drew interest from Teva Pharmaceuticals Inc., which is taking part in an anticipated $25 million-plus financing round while entering a deal with Vaccinex to develop and sell the drug. (BioWorld Today)